Profile data is unavailable for this security.
About the company
ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.
- Revenue in GBP (TTM)9.60k
- Net income in GBP-1.97m
- Incorporated2000
- Employees8.00
- LocationValiRx PLCEliot Park Innovation Centre4 Barling WayNUNEATON CV10 7RHUnited KingdomGBR
- Phone+44 247 679 6496
- Fax+44 203 008 4415
- Websitehttps://www.valirx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovoca Bio PLC | 0.00 | -3.31m | 1.50m | 5.00 | -- | 0.8059 | -- | -- | -0.039 | -0.0349 | 0.00 | 0.0211 | 0.00 | -- | -- | 0.00 | -88.55 | -25.19 | -100.85 | -27.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.05 | -- | -- | -- |
| ValiRx Plc | 9.60k | -1.97m | 2.22m | 8.00 | -- | 0.5761 | -- | 230.92 | -0.0172 | -0.0172 | 0.00008 | 0.0291 | 0.0025 | -- | 0.0639 | -- | -53.19 | -50.57 | -51.14 | -54.77 | 85.00 | -- | -21,512.29 | -103,908.50 | 6.27 | -- | 0.0048 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
| TheraCryf PLC | 396.00k | -3.14m | 2.30m | 9.00 | -- | 0.6312 | -- | 5.80 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| N4 Pharma PLC | 5.86k | -1.12m | 2.57m | 5.00 | -- | 2.05 | -- | 437.90 | -0.0042 | -0.0042 | 0.00002 | 0.0032 | 0.0041 | -- | 0.0421 | 1,172.00 | -79.19 | -57.05 | -83.28 | -61.13 | -- | -- | -19,152.56 | -309,312.80 | -- | -3,023.17 | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Fusion Antibodies PLC | 1.80m | -1.63m | 4.03m | 31.00 | -- | 3.78 | -- | 2.24 | -0.0214 | -0.0214 | 0.0225 | 0.0111 | 1.01 | 3.81 | 2.92 | 58,129.03 | -90.74 | -41.50 | -125.54 | -52.23 | 20.20 | 40.19 | -90.29 | -56.92 | 2.73 | -- | 0.0293 | -- | -60.84 | -12.24 | 14.25 | -- | -72.95 | -- |
| Genflow Biosciences PLC | 0.00 | -1.53m | 6.12m | 5.00 | -- | 7.13 | -- | -- | -0.0051 | -0.0051 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -93.85 | -- | -118.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| ImmuPharma PLC | -69.96k | -2.46m | 6.54m | 5.00 | -- | 2.43 | -- | -- | -0.0065 | -0.0065 | -0.0002 | 0.0065 | -0.019 | -- | -- | -13,992.00 | -66.99 | -86.13 | -111.20 | -106.39 | -- | -- | -- | -8,634.98 | -- | -7.27 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| LungLife AI Inc | 23.04k | -3.55m | 7.32m | 15.00 | -- | 0.3556 | -- | 317.62 | -0.1334 | -0.1334 | 0.0009 | 0.2473 | 0.0027 | -- | 2.90 | 1,536.09 | -42.18 | -- | -47.78 | -- | 100.00 | -- | -15,403.45 | -- | -- | -- | 0.0259 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -2.70m | 7.53m | 67.00 | -- | 9.49 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.002 | 0.00 | -- | -- | -- | -146.70 | -144.15 | -157.81 | -167.75 | -- | -- | -- | -- | -- | -0.45 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Synairgen plc | 0.00 | -6.92m | 9.38m | 36.00 | -- | 0.9751 | -- | -- | -0.0344 | -0.0344 | 0.00 | 0.0475 | 0.00 | -- | -- | 0.00 | -47.18 | -54.01 | -54.24 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
